Pulmonary Vascular Disease |

The Difference of Mortality in Patients With Pulmonar Embolism and Lung Cancer or Other Malignancies FREE TO VIEW

Mustafa Ozhan, MD; Imren Nesil, MD; Simal Coban, MD; Asena Tanyeli Arisoy, MD
Author and Funding Information

Ege University Medical Faculty Dept of Chest Diseases, Izmir, Turkey

Chest. 2015;148(4_MeetingAbstracts):1004A. doi:10.1378/chest.2274266
Text Size: A A A
Published online


SESSION TITLE: Venous Thromboembolism Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: Pulmonary embolism (PE) is a significant risk factor for the mortality of patients with known malignancy. Cancer alone is associated with a 4.1-fold risk of thrombosis, whereas chemotherapy increases the risk 6.5 times. The aim of this study is to analyze the mortality rate in patients hospitalized for acute emboli with known lung carcinoma and other malignancies.

METHODS: The study was enrolled retrospectively in hospitalized patients between January 2012 and 2013 in our teaching hospital. The data of patients hospitalized for acute PE episode was revised for the co-existence of prior malignant disease. All patients are followed for mortality from the diagnosis time to January 2015. All patients were analyzed for for in-hospital mortality, long-term survival and hospital stay days.

RESULTS: Fifty three patients (mean age:65,7±14 years; 20 women) with prior cancer history and acute episode of PE were included in the study. The study patients were divided in two groups; group-1: patients with lung cancer (n:21; mean age 63±13;4 women) ; group-2: patients with other cancer types (n:32; mean age:67,5±15; 16 women). Over-all and in-hospital mortality in the study group was found as 60% (32/53 patients) and 28% (15/53), respectively. Over-all mortality rate was higher in group-1 patients (67%;14/21) when compared to group-2 (56%:18/32) (p:0,02). In-hospital mortality was found as equal between groups (28%, 6/15 for group-1 and 28%, 9/32 in group-2). Total hospital stay period was found as 9,2±5 days. No significant difference was found between groups when compared for number of hospital stay days (8±7 days for group-1 and 10±7 days for group-2,ns). D-Dimer was evaluated in 25 patients. There was no mortality in seven patients who have D-Dimer level less than 4000U but, in 18 patients with D-Dimer was higher than 4000U mortality was 33% (6/18 patients).

CONCLUSIONS: The study showed that the survival period of patients with lung cancer and acute emboli was shorter when compared to patients with emboli and other cancer. This effect is probably due to short survival of the lung cancer. In-hospital mortality and hospital stay days was found as similar between groups.

CLINICAL IMPLICATIONS: Patients with lung cancer and D-Dimer level higher than 4000U must be investigated carefully for fatal PE as the mortality rate was found higher than other malignancies.

DISCLOSURE: The following authors have nothing to disclose: Mustafa Ozhan, Imren Nesil, Simal Coban, Asena Tanyeli Arisoy

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543